0001213900-18-008830.txt : 20180706 0001213900-18-008830.hdr.sgml : 20180706 20180706153651 ACCESSION NUMBER: 0001213900-18-008830 CONFORMED SUBMISSION TYPE: 1-U PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180702 ITEM INFORMATION: Departure of Certain Officers FILED AS OF DATE: 20180706 DATE AS OF CHANGE: 20180706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Emerald Health Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001700800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820669961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 1-U SEC ACT: 1933 Act SEC FILE NUMBER: 24R-00152 FILM NUMBER: 18942492 BUSINESS ADDRESS: STREET 1: 5910 PACIFIC CENTER BLVD STREET 2: SUITE 300, CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 352-0622 MAIL ADDRESS: STREET 1: 5910 PACIFIC CENTER BLVD STREET 2: SUITE 300, CITY: SAN DIEGO STATE: CA ZIP: 92121 1-U 1 f1u070918_emeraldhealth.htm CURRENT REPORT PURSUANT TO REGULATION A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 1-U

 

Current Report Pursuant to Regulation A

 

Date of Report: July 2, 2018

 

EMERALD HEALTH PHARMACEUTICALS INC.

(Exact name of issuer as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation or organization)

 

82-0669961

(I.R.S. Employer Identification Number)

 

5910 Pacific Center Blvd, Suite 300, San Diego, CA 92121

(Full mailing address of principal executive offices)

 

(858) 352-0622

(Issuer’s telephone number, including area code)

 

Title of each class of security issued pursuant to Regulation A: Common Stock.

 

 

 

 

 

 

ITEM 7. DEPARTURE OF CERTAIN OFFICERS

 

On July 2, 2018, the Chief Financial Officer of Emerald Health Pharmaceuticals Inc. (the “Company”), Jill Broadfoot, voluntarily resigned from her employment with the Company, including in her capacity as an officer of the Company, effective as of July 20, 2018.

 

 1 

 

 

SIGNATURES

 

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  EMERALD HEALTH PHARMACEUTICALS INC.,
  a Delaware corporation
     
Date: July 6, 2018 By: /s/ Jim DeMesa
    Jim DeMesa, Chief Executive Officer

 

 2